The Anticancer Application of Delivery Systems for Honokiol and Magnolol

Area of Science:

• Oncology
• Pharmacology
• Nanotechnology

Background:

• Cancer remains a leading global cause of mortality with unmet therapeutic needs.
• Honokiol (HON), a natural compound, has demonstrated potential anticancer properties.
• Improving the efficacy and delivery of HON is crucial for its clinical application.

Purpose of the Study:

• To review the current knowledge on honokiol's anticancer effects and molecular mechanisms.
• To explore the role of nanotechnology-based delivery systems in enhancing HON's efficacy.
• To discuss the potential of combining honokiol with conventional cancer therapies.

Main Methods:

• Comprehensive literature review of in vitro and in vivo studies on honokiol in cancer.
• Analysis of research on honokiol's molecular targets and signaling pathways.
• Evaluation of studies investigating nanotechnology-based delivery systems for honokiol.

Main Results:

• Honokiol exhibits anticancer activity across various common cancer types through multiple mechanisms.
• Nanotechnology-based delivery systems show promise in overcoming honokiol's physicochemical limitations and improving its administration.
• Combination therapy with classical anticancer drugs and honokiol presents an interesting avenue for further investigation.

Conclusions:

• Honokiol demonstrates significant therapeutic potential as an anticancer agent.
• Optimizing honokiol delivery via nanotechnology is key to enhancing its efficacy.
• Further research is warranted to fully elucidate honokiol's mechanisms and applications in diverse cancer types, including combination therapies.